CD24 and acute respiratory distress syndrome: Nadir Arber, MD, Shiran Shapira PhD, Health Promotion Center and Integrated Cancer Prevention Center, Tel Aviv and Tsiodras Sotirios MD, PhD, Attikon University Hospital, National and Kapodistrian University of Athens Medical School presented novel research and clinical trials in EXO-CD24, exosomes enriched with the immune-checkpoint-protein, CD24, as a therapeutic agent against virus-induced hyper-inflammation and ARDS.